Maropitant
neurokinin receptor antagonist
Maropitant , sold under the brand name Cerenia among others, when used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs and in 2012, for cats.
Maropitant mildly reduces intra-procedural inhaled anesthesia dose requirements but does not confer analgesia itself.
Veterinary uses
Injectable maropitant is used in dogs to treat and prevent acute vomiting; tablets are used for preventing vomiting from a variety of causes, though it requires a higher dose to prevent vomiting from motion sickness. The injectable version is also licensed for preventing and treating acute vomiting in cats.
Maropitant is effective in treating vomiting from a variety of causes, including gastroenteritis, chemotherapy, and kidney failure; when given beforehand, it can prevent vomiting caused by using an opioid as a premedication. Some have claimed that maropitant is better at treating vomiting than nausea, pointing to cats with chronic kidney disease who, when receiving maropitant, had a reduction in vomiting but no corresponding increase in appetite.
Maropitant has been used in acute cases of rapid or labored breathing to prevent vomiting that could lead to aspiration pneumonia. It has been given in combination with a benzodiazepine to cats prior to stressful events (such as a veterinary visit) to possibly relieve hypersensitivity.
When compared to other antiemetics, maropitant has similar or greater effectiveness to chlorpromazine and metoclopramide for centrally mediated vomiting induced by apomorphine or xylazine.
Begin with the source’s own compact description: “Maropitant” is neurokinin receptor antagonist. The dossier treats that line as a proposition to test through Maropitant, neurokinin and receptor, not as a finished interpretation.
Why this record matters
The phrase “neurokinin receptor antagonist” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jun 24, 2026. The linked authority identifier is Q3849795. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2007 and 2012.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Maropitant”, its source revision and the description used here.
- Expand the search: follow Maropitant primary sources, Maropitant archive and Maropitant research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Maropitant”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Maropitant” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.